This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
GenMark Diagnostics, Inc.
GenMark Diagnostics, Inc., a leading player in the molecular diagnostics industry, is headquartered in the United States. Founded in 2010, the company has made significant strides in developing innovative testing solutions that enhance patient care. GenMark is renowned for its proprietary ePlex® system, which offers rapid, accurate multiplex testing for infectious diseases, setting it apart in a competitive market. With a strong presence in North America and expanding operations globally, GenMark Diagnostics focuses on delivering advanced diagnostic tools that streamline laboratory workflows. The company has achieved notable milestones, including regulatory approvals and partnerships that bolster its market position. As a pioneer in molecular diagnostics, GenMark continues to drive advancements in healthcare, making it a trusted name in the industry.
DitchCarbon Score
How does GenMark Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GenMark Diagnostics, Inc.'s score of 81 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GenMark Diagnostics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Roche Holding AG, which influences its climate commitments and emissions reporting. As part of its corporate family relationship, GenMark Diagnostics inherits emissions data and sustainability initiatives from Roche Holding AG. However, no specific reduction targets or climate pledges have been outlined for GenMark Diagnostics itself. The absence of documented reduction initiatives suggests that the company may rely on the broader commitments and strategies established by Roche. Roche Holding AG has set ambitious sustainability goals, which may indirectly impact GenMark's operational practices. As a subsidiary, GenMark is expected to align with Roche's climate strategies, although specific details regarding emissions scopes (Scope 1, 2, or 3) and reduction achievements are not provided. In summary, while GenMark Diagnostics, Inc. does not currently report its own emissions data or specific climate commitments, it is positioned within the sustainability framework of Roche Holding AG, which may guide its future environmental initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 249,350,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 114,452,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 6,402,719,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GenMark Diagnostics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
